Survival benefits from reduced-intensity conditioning in allogeneic stem cell transplantation for young lower-risk MDS patients without significant comorbidities

European Journal of Haematology

Volumn 87, Issue 6, 2011, Pages 510-520

  Lee, Sung Eun ^a   Kim, Yoo Jin ^a   Yahng, Seung Ah ^a   Cho, Byung Sik ^a   Eom, Ki Sung ^a   Lee, Seok ^a   Min, Chang Ki ^a   Kim, Hee Je ^a   Cho, Seok Goo ^a   Kim, Dong Wook ^a   Lee, Jong Wook ^a   Min, Woo Sung ^a   Park, Chong Won ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Myeloablative conditioning; Myelodysplastic syndrome; Reduced intensity conditioning; Stem cell transplantation

Indexed keywords

AZACITIDINE;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CAUSE OF DEATH; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; COMORBIDITY; ENGRAFTMENT; FEMALE; FOLLOW UP; HUMAN; MALE; MORTALITY; MULTIVARIATE ANALYSIS; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RELAPSE; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROMES; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; YOUNG ADULT;

EID: 81255136909     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2011.01697.x     Document Type: Article

References (40)

1. Cazzola M, Malcovati L. Myelodysplastic syndromes - coping with ineffective hematopoiesis. N Engl J Med 2005;352:536-8.
2. Mufti GJ, Chen TL. Changing the treatment paradigm in myelodysplastic syndromes. Cancer Control 2008;15(Suppl):14-28.
3. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007;25:3503-10.
4. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88.
5. Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004;104:579-85.
6. Oliansky DM, Antin JH, Bennett JM, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review. Biol Blood Marrow Transplant 2009;15:137-72.
7. Mittelman M, Oster HS, Hoffman M, Neumann D. The lower risk mds patient at risk of rapid progression. Leuk Res 2010;34:1551-5.
8. Kuendgen A, Strupp C, Aivado M, Hildebrandt B, Haas R, Gattermann N, Germing U. Myelodysplastic syndromes in patients younger than age 50. J Clin Oncol 2006;24:5358-65.
9. Sutton L, Chastang C, Ribaud P, et al. Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients societe francaise de greffe de moelle. Blood 1996;88:358-65.
10. Appelbaum FR, Anderson J. Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to ipss score. Leukemia 1998;12(Suppl 1):S25-9.
11. Alessandrino EP, Della Porta MG, Bacigalupo A, et al. Who classification and wpss predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the gruppo italiano trapianto di midollo osseo (gitmo). Blood 2008;112:895-902.
12. de Witte T, Brand R, van Biezen A, et al. Allogeneic stem cell transplantation for patients with refractory anaemia with matched related and unrelated donors: delay of the transplant is associated with inferior survival. Br J Haematol 2009;146:627-36.
13. Finke J, Nagler A. Viewpoint: what is the role of allogeneic haematopoietic cell transplantation in the era of reduced-intensity conditioning - is there still an upper age limit? A focus on myeloid neoplasia. Leukemia 2007;21:1357-62.
14. Shimoni A, Hardan I, Shem-Tov N, Yerushalmi R, Nagler A. Allogeneic hematopoietic stem-cell transplantation in aml and mds using myeloablative versus reduced-intensity conditioning: long-term follow-up. Leukemia 2010;24:1050-2.
15. Sorror ML, Sandmaier BM, Storer BE, Maris MB, Baron F, Maloney DG, Scott BL, Deeg HJ, Appelbaum FR, Storb R. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 2007;25:4246-54.
16. Martino R, Valcarcel D, Brunet S, Sureda A, Sierra J. Comparable non-relapse mortality and survival after hla-identical sibling blood stem cell transplantation with reduced or conventional-intensity preparative regimens for high-risk myelodysplasia or acute myeloid leukemia in first remission. Bone Marrow Transplant 2008;41:33-8.
17. Martino R, Caballero MD, Perez-Simon JA, et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood 2002;100:2243-5.
18. Kroger N, Bornhauser M, Ehninger G, et al. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Ann Hematol 2003;82:336-42.
19. Maris MB, Niederwieser D, Sandmaier BM, et al. Hla-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood 2003;102:2021-30.
20. Sorror ML, Giralt S, Sandmaier BM, De Lima M, Shahjahan M, Maloney DG, Deeg HJ, Appelbaum FR, Storer B, Storb R. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined fhcrc and mdacc experiences. Blood 2007;110:4606-13.
21. Lee S, Kim YJ, Min CK, Kim HJ, Eom KS, Kim DW, Lee JW, Min WS, Kim CC. The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2005;105:3449-57.
22. Min CK, Kim SY, Lee MJ, et al. Vascular endothelial growth factor (vegf) is associated with reduced severity of acute graft-versus-host disease and nonrelapse mortality after allogeneic stem cell transplantation. Bone Marrow Transplant 2006;38:149-56.
23. Kim HJ, Min WS, Cho BS, et al. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant 2009;15:704-17.
24. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED. 1994 consensus conference on acute gvhd grading. Bone Marrow Transplant 1995;15:825-8.
25. Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003;9:215-33.
26. Copelan E, Casper JT, Carter SL, van Burik JA, Hurd D, Mendizabal AM, Wagner JE, Yanovich S, Kernan NA. A scheme for defining cause of death and its application in the t cell depletion trial. Biol Blood Marrow Transplant 2007;13:1469-76.
27. Valcarcel D, Martino R, Sureda A, et al. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies. Eur J Haematol 2005;74:144-51.
28. Deeg HJ, Storer B, Slattery JT, et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 2002;100:1201-7.
29. Takahata M, Hashino S, Okada K, et al. Reduced intensity conditioning regimen with fludarabine, busulfan, and low-dose tbi (flu-bu2-tbi): clinical efficacy in high-risk patients. Am J Hematol 2010;85:243-8.
30. Lee SE, Kim HJ, Min WS, et al. Favorable outcomes of intravenous busulfan, fludarabine, and 400 cgy total body irradiation-based reduced-intensity conditioning allogeneic stem cell transplantation for acute myelogenous leukemia with old age and/or co-morbidities. Int J Hematol 2010;92:342-50.
31. Kim YJ, Kim DW, Lee S, et al. Comparison of 2 preparative regimens for stem cell transplantation from hla-matched sibling donors in patients with advanced myelodysplastic syndrome. Int J Hematol 2005;82:66-71.
32. Cho BS, Kim YJ, Cho SG, et al. The beneficial effect of chronic graft-versus-host disease on the clinical outcome of transplantation with fludarabine/busulfan-based reduced-intensity conditioning for patients with de novo myelodysplastic syndrome. Int J Hematol 2007;85:446-55.
33. Valcarcel D, Martino R, Caballero D, et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol 2008;26:577-84.
34. Cho BS, Lee S, Kim YJ, et al. Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study. Leukemia 2009;23:1763-70.
35. Scott BL, Sandmaier BM, Storer B, Maris MB, Sorror ML, Maloney DG, Chauncey TR, Storb R, Deeg HJ. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 2006;20:128-35.
36. Martino R, Iacobelli S, Brand R, et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using hla-identical sibling donors in myelodysplastic syndromes. Blood 2006;108:836-46.
37. Kim SY, Cho SG, Cho BS, et al. Azacytidine treatment after discontinuation of immunosuppressants in patients with myelodysplastic syndrome and relapse after allo-sct at a single center. Bone Marrow Transplant 2010;45:1375-6.
38. Graef T, Kuendgen A, Fenk R, Zohren F, Haas R, Kobbe G. Successful treatment of relapsed aml after allogeneic stem cell transplantation with azacitidine. Leuk Res 2007;31:257-9.
39. Jabbour E, Giralt S, Kantarjian H, Garcia-Manero G, Jagasia M, Kebriaei P, de Padua L, Shpall EJ, Champlin R, de Lima M. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer 2009;115:1899-905.
40. Khabori MA, El-Emary M, Xu W, Guyatt G, Galal A, Kuruvilla J, Lipton J, Messner H, Gupta V. Impact of intensity of conditioning therapy in patients aged 40-60years with aml/myelodysplastic syndrome undergoing allogeneic transplantation. Bone Marrow Transplant 2011;46:516-22.